

Covalon To Showcase Colactive® Brand Of Advanced Bio-Matrix Dressings At The Symposium On Advanced Wound Care

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Oct. 7, 2016-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that it will be showcasing its advanced wound care line up of products at the Symposium on Advanced Wound Care Fall meeting ("SAWC Fall") in Las Vegas from the 7th to the 9th of October.

"Covalon has supported the efforts of the SAWC for years and we are proud to do so," said Brian Pedlar, Chief Executive Officer of Covalon. "Our position as an emerging leader in the advanced wound care space makes this an important springboard for the following year of activity" Pedlar continued.

SAWC Fall serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings.

In addition to exhibiting, Covalon's ColActive® Transfer will be featured in a case study entitled: *Assessment of a Novel Biomatrix Wound Contact Layer in Conjunction with NPWT on an Abdominal Surgical Wound*, which demonstrates its unique ability to work under Negative Pressure Wound Therapy conditions.

Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician. Covalon's CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both acute and chronic wounds.

Visit the Covalon Technologies Ltd. booth #138 from October 7-9th at the Caesar's Palace Convention Center in Las Vegas.

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Web site: www.covalon.com

Twitter: @covalon

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161007005439/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.
Brian Pedlar, 905.568.8400 x 233
CEO,
bpedlar@covalon.com
Toll free: 1.877.711.6055

<https://ir.covalon.com/press-releases?item=178>